Filing Details

Accession Number:
0001209191-21-021122
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-16 19:16:23
Reporting Period:
2021-03-15
Accepted Time:
2021-03-16 19:16:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1714899 Denali Therapeutics Inc. DNLI () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1666236 E. Steve Krognes C/O Denali Therapeutics Inc.
161 Oyster Point Blvd.
South San Francisco CA 94080
Cfo And Treasurer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-03-15 13,258 $61.16 886,742 No 4 S Indirect See footnote
Common Stock Disposition 2021-03-15 32,326 $62.04 854,416 No 4 S Indirect See footnote
Common Stock Disposition 2021-03-15 3,258 $62.71 851,158 No 4 S Indirect See footnote
Common Stock Disposition 2021-03-15 1,158 $63.67 850,000 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 97,587 Direct
Footnotes
  1. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
  2. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $60.52 to $61.515 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  3. The shares are held of record by The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, for which the Reporting Person serves as trustee.
  4. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $61.52 to $62.50 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  5. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $62.52 to $63.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  6. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $63.67 to $63.69 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
  7. Includes 80,358 restricted stock units.